GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares

Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) announced the pricing of a secondary underwritten public offering of 14,000,000 shares of its common stock, upsized from the initial offering size of 13,000,000 shares. General Electric Company (GE) is expected to exchange the GEHC shares for indebtedness held by Morgan Stanley Bank, N.A. The offering is managed by Morgan Stanley with an option for additional shares to be purchased. The offering is set to close on March 15, 2024, subject to closing conditions.

Insights

Market Research Analyst

The upsizing of the secondary underwritten public offering from 13 million to 14 million shares by GE HealthCare Technologies indicates a potentially higher demand or a strategic move to increase liquidity. Such an offering often leads to dilution of existing shareholders' equity, but in this case, since GE HealthCare is not selling any new shares, the dilution effect is neutralized. Instead, the exchange of shares for debt held by Morgan Stanley Bank, N.A. is a critical aspect to consider.

This transaction could signify a deleveraging strategy by General Electric, which may positively influence GE's balance sheet by reducing its debt burden. Investors and analysts should closely monitor the impact of this debt-for-equity swap on GE's financial leverage ratios and overall financial health. The market's response to this offering could serve as a barometer for investor confidence in GE HealthCare's future prospects and GE's financial restructuring efforts.

Financial Analyst

The granting of an option to the underwriter to purchase additional shares by March 28, 2024, introduces a potential future cash inflow for the selling stockholder but also adds a layer of uncertainty regarding the stock's future price. The transaction's structure, involving a debt-for-equity exchange followed by a secondary offering, is a sophisticated financial maneuver that may impact the stock's volatility in the short term.

Investors should evaluate the terms of the offering, as detailed in the final prospectus supplement, to understand the implications for share price and liquidity. The timing and pricing strategy of selling the shares on the open market or through negotiated transactions could also signal the company's and underwriter's confidence in the stock's valuation and market conditions.

Legal Expert

The offering is being conducted under an automatically effective shelf registration statement, which provides GE HealthCare with the flexibility to sell securities over a prolonged period. The legal framework of such an offering requires meticulous compliance with SEC regulations and the final prospectus supplement will be critical for investors to assess the legal and regulatory aspects of the offering.

It is important for stakeholders to note that the securities cannot be sold in any jurisdiction where such an offering would be unlawful prior to registration or qualification under the securities laws. The legal stipulations and conditions outlined in the prospectus will provide investors with necessary protections and disclosures.

CHICAGO--(BUSINESS WIRE)-- GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 14,000,000 shares of its common stock (the “GEHC Shares”). The Offering was upsized from the previously announced offering size of 13,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Bank, N.A. (the “MS Lender”), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lender. Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriter in the Offering. The selling stockholder in the Offering has granted the underwriter an option to purchase additional shares of GE HealthCare common stock for settlement on or before March 28, 2024.

Morgan Stanley is acting as the sole book-running manager for the Offering. The Offering is expected to close on March 15, 2024, subject to customary closing conditions.

The GEHC Shares will be offered from time to time in one or more transactions on The Nasdaq Stock Market LLC, in the over-the-counter market or through negotiated transactions or otherwise at prices prevailing at the time of sale, at prices related to prevailing prices or at negotiated prices.

The Offering is being made pursuant to an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. A final prospectus supplement and accompanying prospectus describing the terms of the Offering will be filed with the SEC. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and accompanying prospectus relating to the Offering may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with 51,000 colleagues working to create a world where healthcare has no limits.

Forward‐Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain. The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Please also see the “Risk Factors” section of the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312337237/en/

Investor Relations Contact:

Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

Media Contact:

Tor Constantino

+1-585-441-1658

tor.constantino@gehealthcare.com

Source: GE HealthCare Technologies Inc.

FAQ

What is the recent announcement by GE HealthCare Technologies Inc. (GEHC)?

GEHC announced the pricing of a secondary underwritten public offering of 14,000,000 shares of its common stock, upsized from the initial offering size of 13,000,000 shares.

Who is expected to exchange the GEHC shares for indebtedness?

General Electric Company (GE) is expected to exchange the GEHC shares for indebtedness held by Morgan Stanley Bank, N.A.

Who is managing the offering of GEHC shares?

Morgan Stanley is acting as the sole book-running manager for the offering.

When is the offering expected to close?

The offering is expected to close on March 15, 2024, subject to customary closing conditions.

How many shares are included in the offering?

The offering includes 14,000,000 shares of GEHC common stock.